Cardiogenic Shock and Pulmonary Edema¶
Chapter 316 | Part 8: Critical Care Medicine
KEY CLINICAL POINTS¶
- Cardiogenic shock (CS) is a low cardiac output state with life-threatening end-organ hypoperfusion, often due to severe left ventricular dysfunction from myocardial infarction (MI).
- Pulmonary edema in CS is caused by elevated left ventricular end-diastolic pressure (LVEDP) and systemic hypoperfusion, with clinical features including hypotension, tachypnea, and crackles.
- Management includes early revascularization (PCI/CABG), inotropic support (norepinephrine > dopamine), and mechanical circulatory support (MCS) for refractory cases.
- The SCAI classification system (Stages A–E) guides CS severity and treatment urgency, with Stage E requiring palliative care consideration.
- Diagnosis involves echocardiography, pulmonary artery catheterization, and arterial blood gas analysis to differentiate cardiogenic from noncardiogenic pulmonary edema.
1. DEFINITION & OVERVIEW¶
Cardiogenic shock (CS) is a low cardiac output state resulting in life-threatening end-organ hypoperfusion and hypoxia. Pulmonary edema is a common complication due to elevated left ventricular end-diastolic pressure (LVEDP) and systemic hypoperfusion. CS is most frequently caused by severe left ventricular dysfunction from myocardial infarction (MI), with other causes including ventricular septal rupture, acute mitral regurgitation, and right ventricular failure.
Table 316-1: Etiologies of Cardiogenic Shock and Pulmonary Edema¶
| Etiology | Description |
|---|---|
| Acute Myocardial Infarction (MI) | Most common cause, especially anterior MI |
| Left Ventricular Failure | 80% of CS cases due to MI |
| Ventricular Septal Rupture (VSR) | 4% of CS cases |
| Acute Mitral Regurgitation | 7% of CS cases |
| Right Ventricular Failure | 7% of CS cases |
| Takotsubo Syndrome | Transient CS due to stress |
| Myocarditis | Acute fulminant myocarditis |
| Cardiac Tamponade | Pericardial effusion with hemodynamic compromise |
| Pulmonary Embolism | Acute right ventricular strain |
| Aortic Dissection | Aortic insufficiency or tamponade |
Table 31,3: Hemodynamic Patterns¶
| Parameter | Normal Values | CS with LV Failure | Pulmonary Edema | RV Failure | Cardiac Tamponade |
|---|---|---|---|---|---|
| RA (mmHg) | <6 | «› | «› | › | › |
| RVS (mmHg) | <25 | «› | «› | fl«› | «› |
| RVD (mmHg) | 0–12 | «› | «› | ›fl«› | «› |
| PAS (mmHg) | <25 | «› | › | ›fl«› | «› |
| PAD (mmHg) | 0–12 | › | › | fl«› | «› |
| PCW (mmHg) | <6–12 | › | › | fl«› | «› |
| CI (L/min/m²) | ‡2.5 | fl | «fl | › | fl |
| SVR (dyn·s/cmn) | 800–1600 | «› | «› | fl«› | › |
1.1 SCAI Classification of CS¶
The Society for Cardiovascular Angiography and Interventions (SCAI) defines CS severity in five stages: Stage A (at risk), Stage B (beginning), Stage C (classic), Stage D (deteriorating), and Stage E (extremis). Stage E includes patients with cardiac arrest and ongoing CPR/ECMO.
1.2 Pathophysiology¶
CS pathophysiology involves reduced cardiac output, elevated LVEDP, and systemic hypoperfusion. Inflammatory cytokines, nitric oxide (NO) dysregulation, and myocardial ischemia contribute to the spiral of worsening heart failure. Pulmonary edema results from increased hydrostatic pressure in pulmonary capillaries.
2. EPIDEMIOLOGY¶
CS complicating acute MI has decreased to 5–10% due to early reperfusion therapy. STEMI patients have higher CS incidence (10–15%) compared to NSTEMI (2–5%). Mortality rates range from 40–60%, with 50% of survivors readmitted within 1 year and 1/6 dying within the first year. Long-term sequelae include cardiovascular events, cognitive decline, and psychological morbidity.
2.1 Risk Factors¶
Advanced age, prior MI, diabetes, anterior MI location, multivessel coronary disease, and Takotsubo syndrome increase CS risk. Post-cardiac arrest stunning and septic shock also contribute to myocardial depression.
3. ETIOLOGY & PATHOPHYSIOLOGY¶
CS is primarily due to severe left ventricular dysfunction from MI, with other causes including VSR, acute mitral regurgitation, and right ventricular failure. Pathophysiology involves reduced cardiac output, elevated LVEDP, systemic hypoperfusion, and inflammatory cytokine release. Nitric oxide (NO) dysregulation and oxidative stress exacerbate myocardial injury.
3.1 Inflammatory Mechanisms¶
Sepsis and MI trigger systemic inflammation, leading to endothelial dysfunction, microvascular injury, and increased pulmonary capillary permeability. Cytokines like TNF- α and IL-6 contribute to myocardial depression and systemic vasodilation.
4. CLINICAL FEATURES¶
Patients present with dyspnea, hypotension (<90 mmHg systolic or <65 mmHg mean), tachypnea, and crackles. Physical findings include weak pulse, jugular venous distention, and signs of peripheral hypoperfusion (elevated lactate >2 mmol/L). Cardiac markers (troponins, CK-MB) are markedly elevated in MI-associated CS.
4.1 Pulmonary Edema Signs¶
Crackles, wheezing, and pulmonary rales due to alveolar flooding. In severe cases, pulmonary hypertension, hypoxemia, and respiratory failure may occur.
5. DIFFERENTIAL DIAGNOSIS¶
Differentiate cardiogenic pulmonary edema from noncardiogenic causes (e.g., ARDS, fluid overload). Echocardiography and pulmonary artery catheterization help identify left ventricular dysfunction vs. other etiologies.
5.1 Noncardiogenic Edema¶
ARDS, sepsis, and fluid overload from trauma or burns. These typically lack signs of left ventricular dysfunction and respond to diuretics without improvement in cardiac output.
6. INVESTIGATIONS & DIAGNOSIS¶
Diagnostic workup includes ECG (ST elevation in MI), chest X-ray (pulmonary congestion), arterial blood gas (hypoxemia, acidosis), lactate levels (>2 mmol/L), and echocardiography. Pulmonary artery catheterization may confirm elevated PCWP and guide fluid management.
Table 316-2: Echocardiogram Utility in CS¶
| Clinical Question | Information |
|---|---|
| Ventricular Function | Predominantly left, right, or biventricular involvement |
| Etiology | Acute MI, valvular disease, myocarditis |
| Mechanical Complications | VSR, MR, free wall rupture |
| Right Ventricular Function | Assess RV dilation and dysfunction |
| Pulmonary Artery Pressure | Evaluate for pulmonary hypertension |
6.1 Echocardiography¶
Identifies LV dysfunction, mechanical complications (VSR, MR), and right ventricular involvement. Assessments include ejection fraction, valvular function, and intraventricular septal motion.
7. MANAGEMENT & TREATMENT¶
Immediate interventions include revascularization (PCI/CABG), inotropic support (norepinephrine > dopamine), and mechanical circulatory support (MCS) for refractory cases. Fluid management is critical, with diuretics (furosemide) and vasodilators (nitroglycerin) used cautiously.
Table 316-3: Treatment Algorithm for CS¶
| Step | Action | Recommendation |
|---|---|---|
| 1 | Emergency invasive angiography | IB (Immediate) for STEMI/NSTEMI |
| 2 | Immediate echocardiography | IC (Immediate) to assess ventricular function |
| 3 | Fluid challenge | IC if no overt fluid overload |
| 4 | Invasive BP monitoring | IC for hemodynamic support |
| 5 | Pulmonary artery catheter | IIB/C for hemodynamic assessment |
| 6 | Ventilatory support | IC based on ABG results |
| 7 | Inotropes/vasopressors | IIB/C for persistent hypotension |
| 8 | Ultrafiltration | IIB/C for refractory congestion |
| 9 | IABP | IIA/C for selected patients |
| 10 | MCS | IIB/C for refractory CS |
7.1 Revascularization¶
Early PCI is the cornerstone of treatment for MI-associated CS. Culprit-only PCI is preferred over multivessel revascularization to reduce 30-day mortality. CABG is reserved for complex coronary anatomy.
7.2 Inotropic Support¶
Norepinephrine is first-line vasopressor. Dobutamine and milrinone may be used for inotropic support, but their role in CS is limited due to potential myocardial depression.
8. PROGNOSIS & COMPLICATIONS¶
Mortality rates range from 40–60%, with higher risk in Stage E CS. Long-term complications include heart failure, cognitive decline, and recurrent cardiovascular events. Early revascularization and MCS improve outcomes but are associated with significant morbidity.
8.1 Prognostic Factors¶
Age >73 years, prior stroke, elevated glucose (>10.6 mmol/L), elevated creatinine (>1.5 mg/dL), and poor TIMI flow after PCI are associated with worse outcomes.
9. SPECIAL CONSIDERATIONS¶
In septic shock, CS management requires balancing inotropes with vasopressors. Patients with Takotsubo syndrome may respond to beta-blockers. Renal replacement therapy is indicated for refractory volume overload and metabolic acidosis.
9.1 Iatrogenic CS¶
Vasodilators used for pulmonary edema may cause hypotension and coronary hypoperfusion. Morphine use is controversial due to potential mortality risk.
10. KEY POINTS & CLINICAL PEARLS¶
- Early revascularization (PCI/CABG) is the mainstay of CS treatment. 2. Norepinephrine is preferred over dopamine for vasopressors. 3. MCS (Impella, VA-ECMO) is indicated for refractory CS. 4. Echocardiography is critical for diagnosing mechanical complications. 5. Pulmonary artery catheterization helps differentiate cardiogenic from noncardiogenic edema.